Reilly RT, Gottlieb MB, Ercolini AM, Machiels JP, Kane CE, Okoye FI, et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 2000;60:3569–76.

PubMed  CAS  Google Scholar 

Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Kanomata N, et al. CD8(+) tumor-infiltrating lymphocytes contribute to spontaneous “healing” in HER2-positive ductal carcinoma in situ. Cancer Med. 2016;5:1607–18.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol. 1992;23:974–9.

Article  PubMed  CAS  Google Scholar 

Kmieciak M, Knutson KL, Dumur CI, Manjili MH. HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol. 2007;37:675–85.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:463–79.e10.

Article  PubMed  CAS  Google Scholar 

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98.

Article  PubMed  CAS  Google Scholar 

Krishnamurty AT, Shyer JA, Thai M, Gandham V, Buechler MB, Yang YA, et al. LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature. 2022;611:148–54.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10:1330–51.

Article  PubMed  CAS  Google Scholar 

Melero I, Tanos T, Bustamante M, Sanmamed MF, Calvo E, Moreno I, et al. A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors. Sci Transl Med. 2023;15:eabp9229.

Article  PubMed  CAS  Google Scholar 

Tu Z, Karnoub AE. Mesenchymal stem/stromal cells in breast cancer development and management. Semin Cancer Biol. 2022;86:81–92.

Article  PubMed  CAS  Google Scholar 

Raz Y, Cohen N, Shani O, Bell RE, Novitskiy SV, Abramovitz L, et al. Bone marrow-derived fibroblasts are a functionally distinct stromal cell population in breast cancer. J Exp Med. 2018;215:3075–93.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Quante M, Tu SP, Tomita H, Gonda T, Wang SS, Takashi S, et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011;19:257–72.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, et al. Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res. 2004;64:8492–5.

Article  PubMed  CAS  Google Scholar 

Frisbie L, Buckanovich RJ, Coffman L. Carcinoma-associated mesenchymal stem/stromal cells: architects of the pro-tumorigenic tumor microenvironment. Stem Cells. 2022;40:705–15.

Article  PubMed  PubMed Central  Google Scholar 

Rossnagl S, Ghura H, Groth C, Altrock E, Jakob F, Schott S, et al. A subpopulation of stromal cells controls cancer cell homing to the bone marrow. Cancer Res. 2018;78:129–42.

Article  PubMed  CAS  Google Scholar 

Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W. LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res. 2012;72:2980–9.

Article  PubMed  CAS  Google Scholar 

Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69:4134–42.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 2004;96:1593–603.

Article  PubMed  CAS  Google Scholar 

Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 2004;64:1146–51.

Article  PubMed  CAS  Google Scholar 

Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc. 2009;4:102–6.

Article  PubMed  CAS  Google Scholar 

Liu L, Chen J, Zhang H, Ye J, Moore C, Lu C, et al. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Nat Cancer. 2022;3:437–52.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004;5:141–9.

Article  PubMed  CAS  Google Scholar 

Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010;18:160–70.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer—an update. Nat Rev Clin Oncol. 2024;21:675–700.

Article  PubMed  CAS  Google Scholar 

Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, et al. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol. 2007;179:1960–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yu P, Fu YX. Targeting tumors with LIGHT to generate metastasis-clearing immunity. Cytokine Growth Factor Rev. 2008;19:285–94.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson RC, et al. Mesothelin CAR T cells secreting anti-FAP/Anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clin Cancer Res. 2024;30:1859–77.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther. 2009;17:183–90.

Article  PubMed  CAS  Google Scholar 

Feng J, Mantesso A, Sharpe PT. Perivascular cells as mesenchymal stem cells. Expert Opin Biol Ther. 2010;10:1441–51.

Article  PubMed  Google Scholar 

Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat Rev Gastroenterol Hepatol. 2020;17:487–505.